Furthermore, as patients with TNBC do not benefit from targeted therapies directed against ERα such as tamoxifen or HER2 with trastuzumab, they have a poorer prognosis and a higher rate of distant recurrence than women with other breast cancer subtypes [6]. Here, ERBB2 is linked to breast carcinoma.